

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

[RPMI-8226](#)

RRID:CVCL_0014

Type: Cell Line

Proper Citation

RRID:CVCL_0014

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0014

Proper Citation: RRID:CVCL_0014

Description: Cell line RPMI-8226 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:1373872](#), [PMID:1720489](#), [PMID:2041050](#), [PMID:2140233](#), [PMID:2537114](#), [PMID:2563664](#), [PMID:2875788](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:3893568](#), [PMID:4177524](#), [PMID:4366935](#), [PMID:5243066](#), [PMID:5260617](#), [PMID:6042436](#), [PMID:6350451](#), [PMID:8943038](#), [PMID:9290701](#), [PMID:9331090](#), [PMID:9510473](#), [PMID:10087940](#), [PMID:10557056](#), [PMID:10583232](#), [PMID:10700174](#), [PMID:10936422](#), [PMID:11001907](#), [PMID:11154231](#), [PMID:11157491](#), [PMID:11515052](#), [PMID:12068308](#), [PMID:14555701](#), [PMID:15215163](#), [PMID:15748285](#), [PMID:16956823](#), [PMID:16957166](#), [PMID:17088437](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18277095](#), [PMID:18605421](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21173094](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23074853](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29718670](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31465861](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: Produces IgG lambda (PubMed=6042436; ATCC=CCL-155)., Population: African American., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human

Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RPMI-8226

Synonyms: RPMI 8226, RPMI.8226, RPMI8226, RPMI no. 8226, RPMI no 8226, RPMI #8226, 8226, RPMI 8226/S, RPMI-8226S, RPMI8226/S, 8226/S, Roswell Park Memorial Institute 8226, GM02132, GM2132, GM 2132, GM02132C, Simpson

Cross References: BTO:BTO_0000726, CLO:CLO_0008873, CLO:CLO_0031845, EFO:EFO_0002322, MCCL:MCC:0000406, CLDB:cl4182, CLDB:cl4183, CLDB:cl4184, CLDB:cl5252, AddexBio:C0003002/62, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, ATCC:CCL-155, ATCC:CRM-CCL-155, BCRC:60384, BioGRID_ORCS_Cell_line:1003, BioSample:SAMN03471458, BioSample:SAMN03472934, BioSample:SAMN03473581, BioSample:SAMN10988318, cancercellines:CVCL_0014, CCRID:1101HUM-PUMC000083, CCRID:3101HUMTCHu234, Cell_Model_Passport:SIDM00087, CGH-DB:9162-4, ChEMBL-Cells:ChEMBL3307732, ChEMBL-Targets:ChEMBL614882, CLS:300431, Coriell:GM02132, Cosmic:720773, Cosmic:724856, Cosmic:742952, Cosmic:759915, Cosmic:760397, Cosmic:875867, Cosmic:886084, Cosmic:888018, Cosmic:897452, Cosmic:905964, Cosmic:919145, Cosmic:974250, Cosmic:991554, Cosmic:999791, Cosmic:1044255, Cosmic:1092628, Cosmic:1139509, Cosmic:1139639, Cosmic:1175858, Cosmic:1305340, Cosmic:1312326, Cosmic:1762461, Cosmic:1998470, Cosmic:2081405, Cosmic:2159574, Cosmic:2367260, Cosmic:2391801, Cosmic-CLP:905964, DepMap:ACH-000817, DSMZ:ACC-402, DSMZCellDive:ACC-402, ECACC:87012702, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS457ZNO, ENCODE:ENCBS604KZU, GDSC:905964, GEO:GSM2135, GEO:GSM50198, GEO:GSM50261, GEO:GSM143340, GEO:GSM290304, GEO:GSM562819, GEO:GSM621590, GEO:GSM743461, GEO:GSM750813, GEO:GSM799349, GEO:GSM799412, GEO:GSM887548, GEO:GSM888631, GEO:GSM1153419, GEO:GSM1181289, GEO:GSM1181334, GEO:GSM1199922, GEO:GSM1199923, GEO:GSM1199924, GEO:GSM1199925, GEO:GSM1199926, GEO:GSM1199927, GEO:GSM1374855, GEO:GSM1666389, GEO:GSM1670389, GEO:GSM2124680, GEO:GSM7701441, GEO:GSM7701457, IARC_TP53:360, IARC_TP53:27232, IGRhCellID:RPMI8226, IZSLER:BS TCL 92, JCRB:IFO50013, JCRB:JCRB0034, KCLB:10155, LiGeA:CCLE_817, LINCS_LDP:LCL-2049, Lonza:61, NCBI_Iran:C210, NCI-DTP:RPMI-8226, PharmacODB:RPMI8226_1327_2019, PRIDE:PXD001276, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD013859, PRIDE:PXD030239, PRIDE:PXD030304, Progenetix:CVCL_0014, PubChem_Cell_line:CVCL_0014, RCB:RCB3010, SKY/M-FISH/CGH:2743, TKG:TKG 0243, Wikidata:Q54951245

ID: CVCL_0014

Record Creation Time: 20220427T221507+0000

Ratings and Alerts

No rating or validation information has been found for RPMI-8226.

No alerts have been found for RPMI-8226.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 771 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wan YH, et al. (2026) Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. PLoS pathogens, 22(1), e1013772.

Ghaemi B, et al. (2026) Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. Theranostics, 16(6), 2748.

Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer immunology research, 14(4), 528.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Tang H, et al. (2026) Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2. Journal of medicinal chemistry, 69(13), 15317.

Shah UA, et al. (2026) A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. Cancer discovery, 16(4), 697.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(21), e18975.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. Cancer research, 86(8), 2024.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. *Journal of molecular medicine (Berlin, Germany)*, 104(1), 45.

Wang J, et al. (2026) *Clostridium butyricum* alleviates multiple myeloma by remodeling the bone marrow microenvironment and inhibiting PI3K/AKT pathway through the gut-bone axis. *Gut microbes*, 18(1), 2609455.

Gu H, et al. (2026) FAP⁺ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(18), e06239.

Shen N, et al. (2025) HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma. *Cell reports*, 44(5), 115720.

Yin Z, et al. (2025) Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECSO. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 147, 157171.

Wang L, et al. (2025) Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8⁺ T-Cell-Mediated Immunity against Multiple Myeloma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(42), e10888.

Murphy CS, et al. (2025) Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. *Molecular oncology*, 19(6), 1687.

Moreno Rueda LY, et al. (2025) Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. *Cell reports. Medicine*, 6(2), 101925.

Nikolic I, et al. (2025) Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. *Cancer cell*.

Xu MX, et al. (2025) A novel synthesised STAT3 inhibitor exerts potent anti-tumour activity by inducing lysosome-dependent cell death. *British journal of pharmacology*, 182(17), 4041.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.